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Abstract 
 
S-palmitoylation is a lipid modification which regulates membrane-protein association and 
influences protein trafficking, stability or aggregation, thus playing an important role in 
protein signalling. We previously demonstrated that the palmitoylation of Fas, one of the 
death-domain (DD)-containing members of the tumor necrosis factor receptors (TNFR) super 
family, is essential for the redistribution of this receptor into lipid rafts, an obligatory step for 
the death signal transmission. Here we investigate the requirement of protein palmitoylation 
in the activities of other DD-containing death receptors. We show that whereas DR4 is 
palmitoylated, DR5 and TNFR1 are not. Furthermore, DR4 palmitoylation is required for its 
raft localization and its ability to oligomerize, two essential features in TRAIL induced-death 
signal transmission. 
 
 
 
 
 
 
Short title: DR4 palmitoylation and cell death 
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 Introduction 
 
Cell death can be induced by a family of death receptors including Fas 
(TNFRSF6/CD95/Apo-1), TNFR1 (tumor necrosis factor receptor 1, TNFRSF1A), and the 
two TNF-related apoptosis-inducing ligand (TRAIL) receptors DR4 (TRAIL-
R1/TNFRSF10A) and DR5 (TRAIL-R2/TNFRSF10B) [1, 2]. Upon activation by their 
specific ligands, Fas, DR4 and DR5 recruit the adaptor protein FADD (Fas-associated death 
domain) and caspase 8 through their cytoplasmic death domain (DD) to form the DISC 
(death-inducing signalling complex), in which the apoptotic cascade is initiated [3-5] . All 
these receptors are also able to activate non-apoptotic signalling pathways [6-8]. 
Although the molecular events downstream of DISC formation have been intensively 
investigated, the initial steps engaging the death receptors to the apoptotic cell fate are more 
elusive. In this respect, the membrane-proximal events concerning Fas engagement are better 
understood and a precise sequence of events has been described for Fas-mediated cell death. 
Several studies have highlighted the constitutive or Fas ligand (FasL)-induced raft 
microdomain localization of Fas [9-13]. We recently demonstrated that the S-palmitoylation 
of Fas in its cytoplasmic domain, which consists of the reversible addition of a palmitic acid 
to a cysteine, represents an essential signal targeting Fas to these rafts [14]. Moreover, 
palmitoylation allows Fas to associate with the cytoskeletal protein ezrin, reported to be 
critical for Fas-mediated cell death [15]. Indeed, the FasL-induced internalization of Fas 
receptor has been shown to occur in the clathrin-dependent pathway [14, 16, 17] and is a 
prerequisite for DISC formation, which occurs predominantly in endosomes [16].  
However, the mechanisms regulating the initial steps of DR4- or DR5-mediated cell death are 
poorly understood. Several studies have described a constitutive or a raft relocalisation of 
DR4 and DR5 upon TRAIL engagement [18, 19], as well as receptor-mediated endocytosis 
through clathrin-dependant and -independent pathways. Nevertheless, this internalization does 
not seem required for DISC formation and propagation of the death signal [20].  
Here, we have investigated the putative role of palmitoylation for TNFR1 and TRAIL 
receptors. We demonstrate that DR4 is also palmitoylated, and that this post translational 
modification is critical for DR4 localization in rafts and oligomerisation, two crucial steps in 
TRAIL-mediated cell death [18, 21]. 
 
 
Results and discussion 
 
DR4 is palmitoylated but DR5 and TNFR1 are not. 
Protein palmitoylation occurs on cysteine residues located in or near the transmembrane 
domain. We and others have previously demonstrated that human Fas is constitutively 
palmitoylated on cysteine 199 [14, 22]. Sequence analysis revealed that DR4, DR5 and 
TNFR1 also possess one or more cysteines that are potential palmitoylation sites (Fig. 1A in 
blue). The palmitoylation status of the receptors was assessed by incubating HEK293 cells 
transiently expressing Fas, DR4, DR5 or TNFR1 with [3H] palmitate. Immunoprecipitation of 
the receptors followed by immunoblotting and autoradiography showed an incorporation of 
[3H] palmitate by DR4 (Fig. 1B), which could be abolished by competition with the two 
palmitate analogues 2-bromo-palmitate (BrP, Fig. 1B) and 13-oxypalmitate (13-OP, Fig. 1B) 
[23], demonstrating that DR4 is palmitoylated. Under these conditions, we did not detect any 
palmitoylation of DR5 or TNFR1, suggesting that palmitoylation is not a general post 
translational modification for DD receptors. The results of this metabolic [3H] palmitate 
labelling were further confirmed by using a non-radioactive method relying on an acyl-
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biotinyl exchange chemistry, in which the S-palmitoyl thioesther link is specifically cleaved 
by an hydroxylamine exposure and substituted by a biotin moiety (Supplementary Fig.1A). 
Using site directed mutagenesis, we mutated the four putative palmitoylation sites present in 
DR4 and obtained four DR4 mutants: DR4 C261-3S, in which the cysteine triplet was 
mutated, DR4 C268S, DR4 C274S and DR4 C279S. Plasmids encoding DR4 WT and the 
four mutants were transfected into HEK293 cells and the palmitoylation of the receptors was 
assessed. A lack of [3H] palmitate incorporation was observed only when cysteines 261 to 263 
were mutated. Thus, DR4 palmitoylation occurs within this cysteine triplet (Fig. 1C). In order 
to further identify palmitoylated cysteine residue, we generated the single mutants, C261S, 
C262S, and C263S. However, none of the single mutations could abolish DR4 palmitoylation 
(Supplementary Fig.1B), thus rendering the identification of a unique amino acid as the 
palmitoylation site impossible. This result might reflect at least two possible situations that 
might be even combined: (i) several cysteines are palmitoylated at once; (ii) only one cysteine 
is palmitoylated but the palmitoylation site can be interchangeable probably due to the close 
proximity of the two other cysteine residue.  
 
DR4 palmitoylation is required for TRAIL-mediated cell death. 
The function of DR4 palmitoylation was first investigated using a pharmacologic approach. 
The Human Embryonic Kidney cells HEK293, which express DR4 and DR5 at a basal level 
were transiently transfected with DR4 or DR5 to predominantly express DR4 or DR5 
respectively. Pre-treatment with the palmitate analogue 13-oxypalmitate (13-OP) [23] induced 
60 % inhibition of cell death after TRAIL engagement on DR4 transfected cells 
demonstrating the important role of palmitoylation in TRAIL-mediated cell death (Fig. 2A). 
Interestingly, TRAIL-induced cell death was not affected by the 13-OP preincubation on DR5 
overexpressing cells, indicating that the 13-OP inhibitory action is restricted to DR4-mediated 
signalling (Fig.2A). These results were confirmed at the molecular level on PARP cleavage 
(Fig.2B). 
We then analyzed the function of endogenous DR4 palmitoylation in three different cell lines 
which express both DR4 and DR5: the HEK293 cell line, the chronic myeloid leukaemia cell 
line AR230 and the breast cancer cell line MDA-MB-231. The DR4 endogenous 
palmitoylation was checked using the acyl-biotin exchange technique (Supplementary 
Fig.1C). We generated cells expressing DR4 as the main DD containing TRAIL receptor by 
silencing DR5 in the three cell lines using lentivirus expressing shRNA. (Fig.2C). As 
expected, the DR5 knockdown cells were less sensitive to TRAIL-induced cell death 
compared to cells expressing the scramble sequence (Fig. 2C). A two-hour pre-incubation 
with 13-OP induced between 40 and 50 % inhibition of TRAIL-induced cell death in the three 
cell lines expressing the scramble shRNA, indicating a major pro-apoptotic role for 
palmitoylation in TRAIL-mediated cell death. Interestingly, the same level of cell death 
inhibition was achieved by 13-OP pre-treatment when the DR5 expression was silenced, 
suggesting a specific contribution of DR4 palmitoylation in TRAIL-induced death signalling. 
A PARP cleavage analysis confirmed the results obtained with cell death (Fig.2D). 
To investigate the specific role of DR4 palmitoylation with a genetic approach, we transfected 
HEK293 shDR5 cells with an empty vector, DR4 WT and DR4 C261-3S. After verification of 
equal DR4 expression at the cell surface (data not shown), cell death was monitored following 
TRAIL stimulation (Fig. 3A). Inclusion of the empty vector in the experiment allowed the 
role of endogenous DR4 to be distinguished. Upon TRAIL engagement, a significant 
induction of cell death was observed and could be clearly attributed to the transfected DR4 
after 5 hours of TRAIL treatment (compare pcR3- and pcR3 DR4 WT-transfected cells). 
Importantly, cell death of HEK293 shDR5 cells transfected with pcR3 DR4 C261-3S was 
significantly reduced compared to DR4 WT transfected cells demonstrating that this 
palmitoylation-deficient form of DR4 is less efficient to transmit a death signal. One can note 
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that the mutant DR4 keeps some ability to induce cell death (compare pcR3- and pcR3 DR4 
C261-3S-transfected cells). This decrease in cell death was confirmed at the molecular level 
as an inhibition of caspase 8 and PARP cleavage (Fig. 3B).  
We next investigated whether DISC formation was altered in presence of the palmitoylation-
deficient DR4 mutant: a specific recruitment of caspase 8 and FADD to activated DR4 was 
observed upon TRAIL engagement in the presence of the wild-type receptor. In contrast, this 
recruitment was abolished when DR4 C261-3S was expressed (Fig. 2E).  
Altogether, our results demonstrate that DR4 palmitoylation is crucial for DR4 DISC 
formation upon TRAIL engagement and transmission of the death signal.  
 
DR4 palmitoylation is critical for raft localization. 
Palmitoylation can be used as a signal targeting proteins to the raft microdomains [14, 24]. 
We therefore investigated whether DR4 was located in lipid rafts. Post-nuclear supernatant 
(PNS) from HEK293, AR230 and MDA-MB-231 cells were solubilised with polyethylene 
ether Brij 98 and subjected to ultracentrifugation through a sucrose density gradient. The 
detergent-resistant microdomains (DRM) rafts were found in the low-density fractions (LF). 
Sucrose fractions were tested by immunoblotting, using caveolin and clathrin heavy chain 
(CHC) as raft and non-raft markers respectively. Interestingly, both DR4 and DR5 were found 
almost exclusively in the rafts in all tested cell lines (Fig. 4A). No change in raft localization 
was observed for DR4 upon TRAIL stimulation (data not shown) nor when DR5 expression 
was silenced (supplementary Fig.2). Conflicting data have been obtained concerning DR4 and 
DR5 raft localization in several studies. Our results are in agreement with those obtained by 
Song et al who observed constitutive raft localisation for both receptors in non-small cell lung 
carcinoma [18]. However, this is in contradiction with others studies describing constitutive 
non-raft localisation for both DR4 and DR5 and raft recruitment only upon TRAIL 
stimulation [19] or drug treatment [25]. These discrepancies could be attributed to the use of 
different cell lines and different raft isolation techniques [26]. 
To address the question of the functional significance of DR4 and DR5 raft localization, we 
depleted the cells of cholesterol using cholesterol oxidase treatment, which disorganizes the 
lipid rafts. Using conditions that induce a partial loss of death receptor raft localisation (Fig. 
4B, we observed a 60% inhibition of TRAIL-mediated cell death in both HEK293 cells 
overexpressing DR4 and AR230 cells following pre-treatment with cholesterol oxidase (Fig. 
4B). In contrast, staurosporine-induced apoptosis was not affected by cholesterol oxidase 
treatment, confirming the specificity of the treatment to TRAIL signalling (data not shown). 
Thus, DR4 and DR5 raft localisation are necessary for TRAIL-mediated cell death. Similar 
conclusions were driven by Song et al using another cholesterol depleting agent methyl-β-
cyclodextin [18]. 
To directly evaluate the contribution of DR4 palmitoylation to DR4 raft localisation, HEK293 
cells were subjected to lipid raft preparation with or without 13-OP treatment. 13-OP 
exposure induced a 50% delocalisation of endogenous DR4 from the lipid raft whereas DR5 
localisation remains unchanged, suggesting that palmitoylation represents a major signal 
targeting DR4 to the lipid rafts. These results were confirmed by a genetic approach using 
HEK293 cells transfected with DR4 WT and DR4 C261-3S. Unlike the WT receptor, the 
majority of the palmitoylation-deficient DR4 was found in the non-raft fraction, clearly 
demonstrating that DR4 palmitoylation is necessary for raft localisation (Fig. 4D). However, 
an alternative signal targeting DR4 to the rafts appears to exist, since a small proportion of the 
DR4 C261-3S could still be found in the raft fraction. Interestingly, DR5 (Fig. 4A) and 
TNFR1 (data not shown) are also directed to the rafts by a palmitoylation-independent 
mechanism since these two receptors are associated to lipid rafts despite the fact that they are 
not palmitoylated (Fig. 1B). For TNFR1, the death domain itself was reported to be necessary 
and sufficient for this localization [27].  
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Palmitoylation influences DR4 oligomerization. 
Using non-reducing conditions for raft sample preparation, we observed that, in addition to 
causing relocalisation of the monomer form of DR4 into non-raft fractions (Fig. 4D), the 
mutation also affected higher oligomer forms (data not shown). Immunoblotting of non-
reducing total lysates with DR4 antibody showed very different migration patterns for DR4 
WT and DR4 C261-3S. Three different oligomers bands were observed for the WT receptor 
(Fig.5A), while only one band (n°1) was predominant in the C261-3S DR4 sample. Bands 2 
and 3 were only visible after long exposure of the film. Thus, not only the non-raft 
localisation, but also this altered oligomerization capacity of the palmitoylation mutant could 
explain its low ability to induce cell death.  
Moreover, while DR4 WT presented a doublet band for the monomer, only the lower one was 
observed for the palmitoylation-deficient mutant, suggesting that the upper band represents 
palmitoylated DR4, which can be detected in the absence of reducing agents. Thus, only some 
of DR4 WT is palmitoylated.   
DR4 is able to form homo oligomers comprising several DR4 molecules, but also hetero 
oligomers with other TRAIL receptors such as DR5 [4, 19]. In order to investigate the 
composition of oligomers formed by DR4 WT and DR4 C261-3S, we performed 
coimmunoprecipitations with anti-DR4 or anti-DR5 antibodies of HEK293 cells transfected 
with the indicated plasmids (Fig. 4B) and immunoblotted them using anti-DR4 antibody. 
While the oligomerization pattern obtained after the DR4 immunoprecipitation was similar to 
the one obtained from total lysates, only band n°2 contained DR5 and no DR4 C261-3S/DR5 
interaction was observed.  
All together our results pointed out the essential role of the post-translational 
modification of the death receptor DR4 by palmitoylation which we show required for the 
lipid rafts localization of the receptor, and therefore for an efficient transmission of the cell 
death signal. Interestingly we reported that DR4 palmitoylation is not only required for its 
localization to lipid rafts but also for its homo-oligomerization and for its association with 
DR5 (hetero-oligomerization). Future studies will be needed to investigate the exact 
functional correlation of lipid raft association of the TRAIL receptors, the formation of the 
DR4-DR4 or DR4-DR5 complexes and their death-inducing capacities. 
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Material and methods 
 
Antibodies and reagents 
Flag-rhTRAIL was obtained from Alexis. The DR4 and DR5 antibodies used for 
immunoblotting were purchased from Chemicon and Diaclone, and those used for 
immunoprecipitation were from Alexis. The TNFR1 antibodies used for immunoblotting and 
immunoprecipitation were from Santa Cruz and R&D, respectively. Anti-caspase 8 was 
purchased from Cell Signalling, anti-ezrin from Zymed, anti-FADD from MBL, anti-caspase 
3 from BD Bioscience, anti-PARP from Biomol, and anti-Fas (C20), anti-clathrin heavy chain 
and anti-caveolin-1 from Santa Cruz. 
 
Constructs  
pcR3 DR4 C261-3S, pcR3 DR4 C261S, pcR3 DR4 C262S, pcR3 DR4 C263S,  pcR3 DR4 
C268S, pcR3 DR4 C274S and pcR3 DR4 C279S were obtained using the Quikchange site-
directed mutagenesis kit (Qiagen) using pcR3 DR4 as a template and the following primers: 
GTGGCTGTGCTGATTGTCAGTAGTAGCATCGGCTCAGGTTGTGG (forward C261-3S) 
CCACAACCTGAGCCGATGCTACTACTGACAATCAGCACAGCCAC (reverse C261-3S) 
CTGATTGTCAGTTGTTGCATCGGCTCAGG (forward C261S) 
 
CCTGAGCCGATGCAACAACTGACAATCAG (reverse C261S) 
 
CTGATTGTCTGTAGTTGCATCGGCTCAGG (forward C262S) 
 
CCTGAGCCGATGCAACTACAGACAATCAG (reverse C262S) 
 
CTGATTGTCTGTTGTAGCATCGGCTCAGG (forward C263S) 
 
CCTGAGCCGATGCTACAACAGACAATCAG (reverse C263S) 
 
TGCATCGGCTCAGGTAGCGGAGGGGACCCCAAG (forward C268S)   
CTTGGGGTCCCCTCCGCTACCTGAGCCGATGCA (reverse C268S)   
GAGGGGACCCCAAGAGCATGGACAGGGTGTG (forward C274S)      
CACACCCTGTCCATGCTCTTGGGGTCCCCTC (reverse C274S)      
GCATGGACAGGGTGAGTTTCTGGCGCTTGGG (forward C279S) 
CCCAAGCGCCAGAAACTCACCCTGTCCATGC (reverse C279S) 
Lentivirus expressing five different short hairpin RNA (shRNA) targeting DR5 were obtained 
from Sigma (MISSION® shRNA Lentiviral Transduction Particles). The choosen sequence 
for the shRNA is CCGGGCAGAAGATTGAGGACCACTTCTCGAGAAGTGGTCCTCAATCTTCTGC 
TTTTT. A control non-target shRNA lentiviral transduction particle expressing a scramble 
sequence for shRNA was also used. 
 
Cell culture, transfection, lentiviral infection and and cell lysis 
HEK293 human embryonic kidney cells and MDA-MB-231 human epithelial breast cancer 
cells were grown in DMEM supplemented with 10% foetal calf serum. AR230 human chronic 
myeloid leukaemia cells were grown in RPMI supplemented with 10% foetal calf serum. 
HEK293 cells were transiently transfected using the calcium phosphate technique, as 
previously described [28]. For palmitic acid competition with palmitic acid analogues, cells 
were pre-incubated with 100 µM 2-bromo palmitate (Sigma) or 300 µM 13-oxypalmitate for 
2 hours in serum-free conditions. For cholesterol depletion, cells were pre-incubated with 
cholesterol oxidase (Calbiochem) for 2 hours in serum-free medium. HEK293, MDA-MB-
231 and AR230 cells were lysed for Western blotting analysis with Laemmli buffer. 
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For lentiviral infections, HEK293, MDA-MB-231 and AR230 cells were infected with 
lentiviruses expressing five different shRNA sequences targeting DR5 or one shRNA 
scramble sequence with a MOI of 1:1. Cells were then selected for stable integration with 1 
µg/ml puromycin, the efficiency of the knock-down was assessed by western blot and one 
population obtained from one single sequence was chosen. These populations were called 
HEK293, AR230 or MDA-MB-231 shDR5 and compared to populations infected with the 
scramble shRNA (shscramble). 
 
Protein palmitoylation detection. 
We first used a metabolic [3H]palmitate labelling to detect protein palmitoylation. HEK293 
cells transfected with the indicated plasmids were incubated for 5 hours at 37°C with 
[9,10(n)3H] palmitic acid (Amersham, specific activity 60 Ci/mmol) at 0.2 mCi/ml in serum-
free medium. After washing, cells were lysed in buffer A (25 mM HEPES, 150 mM NaCl, 1 
mM EGTA, protease inhibitor cocktail) containing 1% Nonidet P-40 (NP-40) and 10% 
glycerol (lysis buffer) at 4°C, and immunoprecipitated with the indicated antibodies coupled 
to Protein A/G plus agarose beads (Tebu) at 4°C overnight. Immunoprecipitates were 
submitted to SDS-PAGE. Gels were fixed, enhanced using Amplify (Amersham) and exposed 
for autoradiography at –80°C for 10 and 30 days. 
An alternative method to detect protein palmitoylation has been used and adapted from the 
acyl-biotinyl exchange protocol of Drisdel and Green [29, 30] which comprises three 
chemical steps : (i) cell lysates  in  250mM HEPES, 1 mM EDTA  and 2,5% SDS were 
incubated with 0,1% methyl methanethiosulfonate (sigma) at 50°C for 20 minutes to block 
free thiols. (ii) Proteins were precipitated with acetone and resuspended in 1 M 
hydroxylamine pH 7.4 (sigma) which specifically release thioesther-linked palmitoyl moieties 
and restore the modified cysteines to thiols , (iii) which were then mixed with 0,2 mM biotin-
HPDP (Pierce) for 1 hour at room temperature. Biotinylated proteins were purified with 
neutravidin beads (Pierce), separated by SDS-PAGE and submitted to immunoblotting with 
antibody against the protein of interest. Specificity of the experiment is controlled by omitting 
the hydroxylamine treatment. 
 
DISC isolation 
HEK293 cells transfected with pcR3 DR4 WT or pcR3 DR4 C261-3S were stimulated as 
indicated and lysed with buffer A containing 1% NP-40 and 10% glycerol (lysis buffer) at 4 
°C. The PNS obtained after centrifugation at 800g for 10 minutes at 4°C were incubated with 
DR4 antibody (Alexis) overnight and immunoprecipitated with Protein G-sepharose beads 
(Zymed). After 4 washes with lysis buffer, beads were eluted with Laemmli buffer and 
submitted to SDS-PAGE, followed by immunoblotting. 
 
Raft isolation 
Briefly, PNS from HEK293, AR230, and MDA-MB-231 cells (2 × 107) were solubilised with 
1% Brij 98 for 1 hour at 4°C and diluted with 2 ml buffer A containing 2 M sucrose, before 
being placed at the bottom of a step sucrose gradient (1.33-0.9-0.8-0.75-0.7-0.6-0.5-0.4-0.3-
0.2 M) in buffer A. After 16 hours centrifugation at 4°C at 38000 rpm in a SW41 rotor 
(Beckman Coulter), eight 1 ml fractions and one 3 ml fraction (fraction 9) were harvested 
from the top.  
 
Cell death assays 
HEK293 cells transfected or not with the indicated plasmids, AR230 cells or MDA-MB-231 
cells were incubated with the indicated doses of Flag-rhTRAIL plus 1 µg/ml M2 for different 
time periods. HEK293 cell death was measured by morphological observation of trypan blue-
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stained cells. Each sample was counted four independent times per experiment in at least 3 
different experiments.  
AR230 cells and MDA-MB-231 cells were fixed in ice-cold 70% ethanol, washed in 38 mM 
citrate (pH 7.4) and incubated for 20 minutes in 38 mM citrate supplemented with 69 µM 
propidium iodide (Sigma) and 5 µg/ml RNaseA (Sigma). Cells were analysed with a 
FACSCalibur cytometer (Becton Dickinson) and the proportion of sub-G1 particles was 
determined. 
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Figure legends 
 
Figure 1: DR4 is palmitoylated in the cytoplasmic region. (A) Sequence comparison of the 
membrane-proximal cytoplasmic region of human Fas, TNFR1, DR4 and DR5. The 
transmembrane sequence is represented in red, the cytoplasmic part in black and cysteine 
residues providing putative sites for palmitoylation are highlighted in blue. (B) DR4 is 
palmitoylated. HEK293 cells transiently expressing Fas, DR4, DR5 or TNFR1 were subjected 
to metabolic labelling with [3H] palmitate. Death receptors were immunoprecipitated with 
specific antibody and analysed by both autoradiography (bottom part) and immunoblotting 
(ECL). The palmitic analogues bromo-palmitate (BrP) and 13-oxypalmitate (13-OP) were 
used to compete with [3H] palmitate and confirm the specificity of the labelling (right panel). 
(C) DR4 is palmitoylated on the cysteine triplet at 261-3. The four putative palmitoylation 
sites were mutated from cysteine to serine by site-directed mutagenesis and the palmitoylation 
status was assessed as in (B). 
 
Figure 2: The palmitic acid analogue 13-OP inhibits TRAIL-induced DR4-mediated cell 
death. (A) HEK293 cells transiently transfected with pcR3 DR4 or pcR3 DR5 were pre-
incubated with 300 µM of the palmitic acid analogue 13-OP for 2 hours or left untreated. Cell 
death was monitored after 3 hours of 250 ng/ml Flag-rhTRAIL plus 1 µg/ml M2. (B) HEK293 
cells transiently expressing DR4 or DR5 were treated as in (A). Cell lysates were separated by 
SDS-PAGE and submitted to immunoblotting to assess PARP cleavage. (C) HEK293, AR230 
and MDA-MB-231 cells expressing shRNA targeting DR5 or a scramble (sc) sequence were 
pre-treated for 2 hours with 300 µM 13-OP and then exposed to 250 ng/ml Flag-rhTRAIL 
plus 1 µg/ml M2. Cell death was detected after five (HEK293 and AR230) or four hours 
(MDA-MB-231). Efficient DR5 knock-down was controlled by western blot. (D) MDA-MB-
231 shDR5 or MDA-MB-231 scramble cells were treated as in (C). Cells were lysed with 
laemmli buffer and PARP cleavage was assessed by western blot. 
 
Figure 3: DR4 palmitoylation on the cysteine triplet 261-3 is required for efficient 
TRAIL-induced cell death. (A) HEK293 shDR5 cells transiently transfected with pcR3, 
pcR3 DR4 WT or pcR3 DR4 C261-3S were subjected to TRAIL-induced cell death with the 
indicated Flag-rhTRAIL dose plus 1 µg/ml M2. Cell death was detected after 5 hours 
incubation. (B) HEK293 cells transiently transfected with pcR3 DR4 WT or pcR3 DR4 C261-
3S and treated with 250 ng/ml Flag-rhTRAIL plus 1 µg/ml M2 were lysed after 3 hours 
treatment and submitted to Western blotting. (C) DISC isolation was performed on HEK293 
cells transiently expressing DR4 WT or DR4 C261-3S and stimulated for 15 minutes with 250 
ng/ml Flag-rhTRAIL plus 1 µg/ml M2.  
 
Figure 4: Palmitoylation is required to target DR4 to the rafts. (A) Brij 98-solubilised 
PNS from HEK293, AR230 and MDA-MB-231 cells were submitted to low-density, 
detergent-resistant membrane microdomain (DRM) preparation. DRMs are localized in 
fractions 1-4 and referred as light fractions (LF). HF denotes high-density fractions where 
detergent-solubilized proteins or those associated with high-density microdomains are 
localized. Caveolin and CHC serve as markers for LF and HF, respectively. The nine resulting 
sucrose fractions were immunoblotted with the indicated antibodies. (B) HEK293 cells 
transfected with pcR3 DR4 and AR230 cells were preincubated for 2 hours with 2 U/ml 
cholesterol oxidase. Cell death was monitored after 3 hours of 250 ng/ml Flag-rhTRAIL plus 
1 µg/ml M2. In parallel, DR4 and DR5 DRM delocalisation was confirmed by submitted 
HEK293 cells treated with the indicated dose of cholesterol oxidase to DRM preparation. (C) 
HEK293 cells were treated with 300 µM 13-OP for 2 hours before DRM preparation as in 
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(A). Endogenous DR4 delocalisation from the raft was monitored by western blot. (D) 
HEK293 cells transfected with pcR3 DR4 WT or pcR3 DR4 C261-3S were subjected to raft 
preparation as in (A) and exogenous DR4 expression detected by immunoblotting.  
. 
Figure 5: DR4 oligomerization profile is altered in the palmitoylation-deficient mutant. 
(A) Non-reducing SDS-PAGE of total lysates from HEK293 cells transfected with pcR3 DR4 
WT or pcR3 DR4 C261-3S immunoblotted with anti-DR4 antibody. (B) HEK293 cells were 
transfected with vectors encoding the indicated proteins. Immunoprecipitation with anti-DR4 
antibody (left panel) and anti-DR5 antibody (right panel) was followed by SDS-PAGE under 
non-reducing conditions and immunoblotting with anti-DR4 antibody. 
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